• 1
    Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 506
  • 2
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates. Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 5461
  • 3
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. prevalence and predictors. JAMA 1999; 281: 53744
  • 4
    Virag R, Beck-Ardilly L. Nosology, epidemiology, clinical quantification of erectile dysfunctions. Rev Med 1997; 18 (Suppl. 1): 10s13s
  • 5
    Dunn KM, Croft PR, Hackett GI. Sexual problems. a study of the prevalence and need for health care in the general population. Family Prac 1998; 15: 51924
  • 6
    Parazzini F, Menchini FF, Bortolotti A et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000; 37: 439
  • 7
    Pinnock CB, Stapleton AM, Marshall VR. Erectile dysfunction in the community: a prevalence study. Med J Australia 1999; 171: 3537
  • 8
    Koskimaki J, Hakama M, Huhtala H, Tammela TL. Effect of erectile dysfunction on frequency of intercourse: a population based prevalence study in Finland. J Urol 2000; 164: 36770
  • 9
    Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999; 161: 511
  • 10
    Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 3026
  • 11
    Stanford JL, Feng Z, Hamilton AS et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 35460
  • 12
    Benoit RM, Naslund MJ, Cohen JK. Complications after radical retropubic prostatectomy in the Medicare population. Urology 2000; 56: 11620
  • 13
    Aversa A, Rocchietti-March M, Botta D et al. Pharmacology of male sexual dysfunction. Minerva Endocrinologica 1998; 23: 1725
  • 14
    Morales A, Heaton JP, Carson CC. Andropause: a misnomer for a true clinical entity. J Urol 2000; 163: 70512
  • 15
    Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000; 164: 3715
  • 16
    Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000; 86: 41F45F
  • 17
    Boyle P, Robertson C, Mazzetta C et al. International variation in the prevalence of lower urinary tract symptoms in men and women in four centres. The UREPIK study. BJU Int 2003; 92: 40914.
  • 18
    O'Leary MP, Fowler FJ, Lenderking WR et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697706
  • 19
    Gandek B, Ware JE, Aaronson NK et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 11718
  • 20
    Barry MJ, Fowler FJ, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the AUA. J Urol 1992; 148: 154957
  • 21
    Brody J. Prospects for an ageing population. Nature 1985; 315: 4636
  • 22
    McVary KT. The role of the autonomic nervous system tone in BPH symptomatology. J Urol 2002; 167 (Suppl. 4): A863
  • 23
    Wyllie MG, Andersson K-E. Orally active agents. The potential of alpha-adrenoceptor antagonists. In CarsonC, KirbyR, GoldsteinI eds. Textbook of Erectile Dysfunction. Oxford: Isis Medical Media, 1999: 317 – 22
  • 24
    Nickel JC, Fradet Y, Boake RC et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two Year Study. Can Med Assoc J 1996; 155: 12519
  • 25
    Narayan P, Lepor H. Long-term, open-label, phase III multicentre study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 46670
  • 26
    Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomised, placebo-controlled trial. Urology 2001; 58: 9539